3.38
-0.03(-0.88%)
Currency In USD
| Previous Close | 3.41 |
| Open | 3.38 |
| Day High | 3.44 |
| Day Low | 3.32 |
| 52-Week High | 20.7 |
| 52-Week Low | 2.45 |
| Volume | 7,718 |
| Average Volume | 75,518 |
| Market Cap | 10.79M |
| PE | -0.42 |
| EPS | -8.07 |
| Moving Average 50 Days | 3.32 |
| Moving Average 200 Days | 5.13 |
| Change | -0.03 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.23 as of February 21, 2026 at a share price of $3.38. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $5.01 as of February 21, 2026 at a share price of $3.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences Expands Global Intellectual Property Estate
GlobeNewswire Inc.
Feb 17, 2026 1:05 PM GMT
Strengthens Protection Around Broad Portfolio of Cancer-Targeting Drug Conjugates and Enabling Technologies Provides Key Coverage Across Europe Ahead of Planned 3Q26 Filing for Conditional Marketing Approval with the European Medicines Agency (EMA) f
Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 09, 2026 1:05 PM GMT
Following Guidance from the European Medicines Agency’s (EMA) Scientific Advice Working Party (SAWP) Regarding Iopofosine I 131 for the Treatment of Waldenstrom’s Macroglobulinemia (WM), Expects to Submit for Conditional Marketing Approval in Europe
Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies
GlobeNewswire Inc.
Dec 16, 2025 1:05 PM GMT
Supports Development of Phospholipid Radioconjugate (PRC) CLR-225 for the Treatment of Solid TumorsFLORHAM PARK, N.J. and LANSING, Mich., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmac